Latanoprost acid_product_DataBase

Bioactivity	Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2].
Invitro	Latanoprost acid (10-20 μM;24 hours) reduces he protein expressions of c-fos and NFATc1[1]. Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK[1]. Latanoprost acid (10 μM, 20 μM) significantly inhibits the mature osteoclast formation[1]. Western Blot Analysis[1] Cell Line:
In Vivo	Latanoprost acid (i.p.; 20 mg/kg; once a day for 7 days) notably prevents LPS-induced bone destruction at a dose of 20mg/kg[1]. Animal Model:
Name	Latanoprost acid
CAS	41639-83-2
Formula	C23H34O5
Molar Mass	390.51
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Weinreb RN, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S53-64. [2]. Xu X, et al. The prevention of latanoprost on osteoclastgenesis in vitro and lipopolysaccharide-induced murine calvaria osteolysis in vivo. J Cell Biochem. 2018 Jun;119(6):4680-4691.

PeptideDB